A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

November 30, 2026

Conditions
Gastric Cancer
Interventions
DRUG

Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)

"Adebrelimab injection:Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate:Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound):Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes."

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT06339216 - A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | Biotech Hunter | Biotech Hunter